Randall Holcomb
Papers
2
Total Citations
192
H-Index
2
About
Randall Holcomb is a pioneering researcher in the field of cell transplantation therapy for Duchenne muscular dystrophy (DMD). His work focuses on the feasibility, safety, and efficacy of myoblast transfer therapy (MTT) as an experimental treatment for this devastating genetic disorder. Holcomb’s most impactful contributions include a landmark Phase II study involving 21 DMD boys aged 6–14, where five billion normal myoblasts were injected into each patient’s lower limbs to assess muscle strengthening—a study that has garnered 106 citations. He further expanded this work in a 1993 study with 32 boys, half nonambulatory, demonstrating the potential of MTT even in advanced disease stages, earning 86 citations. Holcomb’s research has been instrumental in establishing the foundational safety and efficacy data for cell-based therapies in muscular dystrophy, paving the way for future regenerative medicine approaches. His rigorous clinical trials remain widely referenced, underscoring his lasting impact on neuromuscular disease research.
Research Focus
Key Achievements
Top Papers
- 1
- 2